000			01935 a2200529 4500
005			20250516214617.0
264		0	_c20150623
008			201506s 0 0 eng d
022			_a1471-2334
024	7		_a10.1186/1471-2334-14-289 _2doi
040			_aNLM _beng _cNLM
100	1		_aStryjewski, Martin E
245	0	0	_aA randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. _h[electronic resource]
260			_bBMC infectious diseases _cMay 2014
300			_a289 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAminoglycosides _xadverse effects
650	0	4	_aAnti-Bacterial Agents _xtherapeutic use
650	0	4	_aBacteremia _xdrug therapy
650	0	4	_aCatheter-Related Infections _xcomplications
650	0	4	_aDouble-Blind Method
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aLipoglycopeptides
650	0	4	_aMale
650	0	4	_aMethicillin-Resistant Staphylococcus aureus _xdrug effects
650	0	4	_aMiddle Aged
650	0	4	_aPenicillins _xtherapeutic use
650	0	4	_aStaphylococcal Infections _xdrug therapy
650	0	4	_aStaphylococcus aureus _xdrug effects
650	0	4	_aTreatment Outcome
650	0	4	_aVancomycin _xtherapeutic use
700	1		_aLentnek, Arnold
700	1		_aO'Riordan, William
700	1		_aPullman, John
700	1		_aTambyah, Paul Anantharajah
700	1		_aMiró, Jose M
700	1		_aFowler, Vance G
700	1		_aBarriere, Steven L
700	1		_aKitt, Michael M
700	1		_aCorey, G Ralph
773	0		_tBMC infectious diseases _gvol. 14 _gp. 289
856	4	0	_uhttps://doi.org/10.1186/1471-2334-14-289 _zAvailable from publisher's website
999			_c23876034 _d23876034